DACLA

Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype and 3 infection.

It is marketed under the name

DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form.

Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

HCV is a single-stranded

RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients 8.

Daclatasvir was the first drug with demonstrated safety and therapeutic efficacy in treating HCV genotype 3 without the need for co-administration of interferon or Ribavirin.

It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV.

Binding to the N-terminus of the

D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.

Daclatasvir is shown to target both the cis.

• and trans-acting functions of NS5A and disrupts the function of new HCV replication complexes by modulating the NS5A phosphorylation status 3.

The most common critical

NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype 3 patients.

According to 2017 American Association for the Study of Liver Diseases (AASLD), 60 mg of daclatasvir is recommended with 400 mg Sofosbuvir for genotype 1a/b patients with or without cirrhosis as second-line therapy.

The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis.

Combination therapies that include daclatasir can be used for challenging-to-treat patients who have HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV 9.

The therapy is intended to cure or achieve a sustained virologic response (SVR12), after 12 weeks of daily therapy.

SVR and eradication of

HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality 6.

Daclatasvir was FDA-approved in July for use with Sofosbuvir (Sovaldi) with or without Ribavirin to treat HCV genotype and 3 infections.

SVR12 in HCV genotype 1a-infected treatment-naïve subjects without and with cirrhosis undergoing daclatasvir and Sofosbuvir therapy were 88% and 99%, respectively Label.

The same dosing regimen in treatment-naïve patients with HCV genotype 3 infection with or without cirrhosis achieved SVR12 rates of 71% and 98%, respectively Label.

Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection.

The dosing regimen of 60 mg daclatasvir 60 mg with 400 mg sofosbuvir once a day is recommended for both genontypes.

Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients.

NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.

Daclatasvir is a direct-acting antiviral agent that targets the NS5A and causes a decrease in serum HCV RNA levels.

It disrupts

HCV replication by specifically inhibiting the critical functions of an NS5A protein in the replication complex 3.

It is shown to cause downregulation of the hyperphosphorylation of NS5A.

It does not appear to prolong the QT interval even when given at 3 times the maximum recommended dose.

Studies demonstrated that peak plasma concentrations typically occurred within 2 hours after administration of multiple oral doses ranging from 1-100 mg once daily.

Steady state is reached after approximately 4 days of once-daily daclatasvir administration.

The absolute bioavailability of the tablet formulation is 67%.

The approximate volume of distribution of daclatasvir is 47 L in patients who was Oral administered 60 mg tablet followed by 100 µg -daclatasvir Intravenous.

Daclastavir is a substrate of

CYP3A enzymes where its metabolism is predominantly mediated by CYP3A4 isoform.

Oxidative pathways included δ-oxidation of the pyrrolidine moiety, resulting in ring opening to an aminoaldehyde intermediate followed by an intramolecular reaction between the aldehyde and the proximal imidazole nitrogen atom 7.

High proportion of the drug in the plasma (greater than 97%) is in the unchanged form.

Approximately 88% of total dose of daclatasvir is eliminated into bile and feces in which 53% remains as unchanged form, while 6.6% of the total dose is eliminated primarily unchanged in the urine.

Following multiple dose administration of daclatasvir in HCV-infected subjects, with doses ranging from 1 mg to 100 mg once daily, the terminal elimination half-life of daclatasvir ranged from approximately 12-15 hours.

In subjects who received daclatasvir 60 mg tablet Oral followed by 100 µg radiolabeled daclatasvir Intravenous, the total clearance was 4.2 L/h.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

The most common adverse effects experienced in patients undergoing daclatasvir and sofosbuvir therapy include headache, fatigue, nausea and diarrhea.

Similar side effects are seen when ribavirin is added, in addition to rash, insomnia, anemia, dizziness and somnolence.

There are postmarketing cases that link serious symptomatic bradycardia with Daklinza when used in conjunction with sofosbuvir and amiodarone.

Coadministration of these three drugs is not recommended unless there are no other alternatives.